Switch to Ralph Durand's research page...

2007

1. Moiseenko V, Duzenli C, Durand RE. In vitro study of cell survival following dynamic MLC intensity-modulated radiation therapy dose delivery. Med Phys. 34(4):1514-20. (2007).
    [View Abstract - PubMed 17500482]  Request Paper

2006

2. Durand RE, Aquino-Parsons C. The fate of hypoxic (pimonidazole-labelled) cells in human cervix tumours undergoing chemo-radiotherapy. Radiother Oncol. 80(2):138-42. Epub 2006 Aug 17. (2006).
    [View Abstract - PubMed 16916562]  Request Paper

3. Holzscheiter MH, Bassler N, Agazaryan N, Beyer G, Blackmore E, DeMarco JJ, Doser M, Durand RE, Hartley O, Iwamoto KS, Knudsen HV, Landua R, Maggiore C, McBride WH, Moller SP, Petersen J, Skarsgard LD, Smathers JB, Solberg TD, Uggerhoj UI, Vranjes S, Withers HR, Wong M, Wouters BG. The biological effectiveness of antiproton irradiation. Radiother Oncol. 81(3):233-42. Epub 2006 Oct 27. (2006).
    [View Abstract - PubMed 17069916]  Request Paper

2005

4. Olive PL, Durand RE. Heterogeneity in DNA damage using the comet assay. Cytometry A. 66(1):1-8. (2005).
    [View Abstract - PubMed 15924303]  Request Paper

5. Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, Knowling MA, Coppin CM, Weir L, Gelmon K, Le N, Durand R, Coldman AJ, Manji M. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 97(2):116-26. (2005).
    [View Abstract - PubMed 15657341]  Request Paper

2004

6. Bennewith KL, Durand RE. Quantifying transient hypoxia in human tumor xenografts by flow cytometry. Cancer Res 64(17):6183-9. (2004).
    [View Abstract - PubMed 15342403]  Request Paper

7. Durand RE, Aquino-Parsons C. Predicting response to treatment in human cancers of the uterine cervix: sequential biopsies during external beam radiotherapy. Int J Radiat Oncol Biol Phys 58(2):555-60. (2004).
    [View Abstract - PubMed 14751527]  Request Paper

2002

8. Bennewith KL, Raleigh JA, Durand RE. Orally administered pimonidazole to label hypoxic tumor cells. Cancer Res 62(23):6827-30. (2002).
    [View Abstract - PubMed 12460894]  Request Paper

9. Olive PL, Banath JP, Durand RE. The range of oxygenation in SiHa tumor xenografts. Radiat Res 158(2):159-66. (2002).
    [View Abstract - PubMed 12105985]  Request Paper

2001

10. Bennewith KL, Durand RE. Drug-induced alterations in tumour perfusion yield increases in tumour cell radiosensitivity. Br J Cancer 85(10):1577-84. (2001).
     [View Abstract - PubMed 11720448]  Request Paper

11. Durand RE, Aquino-Parsons C. Non-constant tumour blood flow: Implications for therapy Acta Oncol 40:862-869 (2001).
     Request Paper

12. Durand RE, Aquino-Parsons C. Clinical relevance of intermittent tumour blood flow. Acta Oncol 40(8):929-36. (2001).
     [View Abstract - PubMed 11845957]  Request Paper

2000

13. Durand RE, LePard NE. Effects of mitomycin C on the oxygenation and radiosensitivity of murine and human tumours in mice. Radiother and Oncol 5:245-256 (2000).
     [View Abstract - PubMed 10927145]  Request Paper

1999

14. Sham E, Durand RE. Cell kinetics and repopulation parameters of irradiated xenograft tumours in SCID mice: Comparison of two dose-fractionation regimens. Eur J Cancer 35:850-858 (1999).
     [View Abstract - PubMed 10717061]  Request Paper

1998

15. Durand RE, Raleigh JA. Identification of non-proliferating but viable hypoxic tumor cells in vivo. Cancer Res 58:3547-3550 (1998).
     [View Abstract - PubMed 9721858]  Request Paper

16. Huang P, Olive PL, Durand RE. Use of the comet assay for assessment of drug resistance and its modulation. Br J Cancer 77:412-416 (1998).
     [View Abstract - PubMed 9472636]  Request Paper

1997

17. Durand RE, LePard NE. Tumour blood flow influences combined radiation and doxorubicin treatments. Radiother and Oncol 42:171-179 (1997).
     [View Abstract - PubMed 9106927]  Request Paper